RESOURCES
Browse our content
Posters
Suspension based adenovirus production in scale-X™️ fixed-bed bioreactor
March 23, 2023
Posters
Design of Experiment, a powerful tool to simplify viral production process development
November 28, 2022
Videos
Critical decision to address during the viral vector manufacturing
September 21, 2022
Articles
How standardized viral vector platforms can drive better service from CDMOs
July 12, 2022
Webinars
Joint webinar with Pall Corporations – Pall’s Accelerator℠ Integrated Solutions: Supporting Exothera to meet the high demand for viral vector GMP manufacturing.
June 21, 2022
Podcasts
Using End-to-End Integrated Solutions to meet the High Demand for Viral Vector GMP Manufacturing
June 14, 2022
Webinars
Joint webinar with POLYPLUS – Taking a right first-time approach to optimize end-to-end viral vector manufacturing
June 9, 2022
Reports
Biopharma CDMO Benchmark Report – What customers want from their CDMO
April 15, 2022
Articles
Serum-based media concerns in viral vector manufacturing
March 15, 2022
Articles
Are modern scalable bioreactors the right cell culture strategy for gene and cell therapy success?
January 31, 2022
Articles
Gene and cell therapy manufacturing: how to design your stable cell line strategy?
January 5, 2022
Posters
Adaptation of suspension-based Adenovirus production process to scale-X™ technology
December 21, 2021
White Papers
The landscape for viral vector upstream processes – PROS and CONS
December 11, 2021
Brochures
Exothera Capabilities
October 19, 2021
Infographics
Timeline of viral vector-based Cell & Gene therapy approvals
May 6, 2021
Infographics
Worldwide approved gene therapies based on viral vectors
February 21, 2021
Infographics
Plasmid manufacturing capacity around the world
November 30, 2020